Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review
The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Ketamine and its enantiomer S-ketamine (esketamine) are promising candidates to produce a rapid-onset antidepressant effect in treatment-resistant depression. Ketamine causes continued blockade of the glutamate N-methyl-D-aspartate (NMDA) receptor, though this might not primarily mediate the antidepressant effect. Alternative hypotheses include selectivity for the NMDA receptor subtype containing the NMDA receptor subunit 2B (NR2B), inhibition of the phosphorylation of the eukaryotic elongation factor 2 (eEF2) kinase, increased expression of brain-derived neurotrophic factor (BDNF) and tropomyosin receptor kinase B (TrKB), and activation of the mammalian target of rapamycin (mTOR) signaling pathway, alongside other independent actions attributed to the ketamine metabolism to R-hydroxynorketamine (R-HNK). The enantiomer S-ketamine (esketamine) displays approximately fourfold greater affinity for the glutamate NMDA receptor in vitro than R-ketamine. Proof-of-concept single-dose and repeat-dose studies with intravenous ketamine show a significant antidepressant and probably antisuicidal effect in the short term, with response rates over 60% as early as 4.5 h after a single dose, with a sustained effect after 24 h, and over 40% after 7 days. This response can be further sustained over several weeks with repeated doses (two to three doses per week). Tolerability seems acceptable in the short term, with transient elevation of blood pressure and mild and transient dissociative and p…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Longer term safety signals are still emerging, including concerns related to abuse liability, urinary symptoms, and cumulative neurocognitive effects with repeated exposure [82,86,90].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [86]
In the citing paper
“Dissociative and psychotomimetic effects are common, typically transient, and sometimes accompanied by cardiovascular changes [85,86,87].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [86]
In the citing paper
“These acute and transient effects include an increase in blood pressure (usually asymptomatic), nausea and vomiting, perceptual disturbance, drowsiness, dizziness and dissociation.43,76–78”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [76]
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010) · JAMA · doi:10.1001/jama.2009.1943 · Cited by 2,009
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Homayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Mechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127
Rush, A. J. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.11.1905 · Cited by 870
Research works printed but not linked: 1
- Short B, Fong J, Galvez V, Shelker W, Loo CK. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry [Internet]. 2017; Available from: http://linkinghub.elsevier.com/retrieve/pii/S2215036617302729 .
Cited by
Items 101–200 of 290
Song, Z., Miao, M., Huang, F., Hu, L., Yang, X., Cui, W., Yu, Y., Wang, G. L., Wang, C., & Zhang, L. (2025) · Nature Communications · doi:10.1038/s41467-025-62933-1 · Cited by 18
“…as an S-enantiomer of racemic ketamine and a novel N-methyl-D-aspartate receptor (NMDAR) antagonist with a greater af fi nity as compared to ketamine, simultaneously, esketamine has been identi fi ed to exhibit stronger anesthetic and analgesic properties with fewer side-effects than ketamine 14,15 .”
Advances in calcium signalling research for the diagnosis and treatment of depression
Li, L., Yao, M., Meng, J., Zhong, Z., Nan, N., Kazemi, A. H., Guo, J., Liu, C., & Jiang, Y. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2620329 · Cited by 21
“Additionally, one of its metabolites, R-hydroxynorketamine, has been shown to produce antidepressant-like effects independently of NMDAR blockade [112].”
Guo, F., Zhang, B., Shen, F., Li, Q., Song, Y., Li, T., Zhang, Y.-M., Du, W., Li, Y., Liu, W., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16420 · Cited by 17
“Ketamine is the most well studied of these agents (Li et al., 2010; Molero et al., 2018), but its potential for abuse and side effects raise concerns (Short et al., 2018).”
Fava, M., Stahl, S. M., Pani, L., Martin, S. D., Cutler, A. J., Maletic, V., Gorodetzky, C. W., Vocci, F. J., Sapienza, F. L., Kosten, T. R., et al. (2024) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.24m15265 · Cited by 18
Developments in the discovery and design of intranasal antidepressants
Panek, M., Kawalec, P., Pilc, A., & Lasoń, W. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1776697 · Cited by 17
Casaril, A. M., Lourenço, D. D. A., Domingues, M., Smaniotto, T. Â., Birmann, P. T., Vieira, B. M., Sonego, M. S., Seixas, F. K., Collares, T. V., Lenardao, E. J., et al. (2021) · Comprehensive Psychoneuroendocrinology · doi:10.1016/j.cpnec.2021.100054 · Cited by 17
Li, W., Zhou, Y., Liu, W., Wang, C., Lan, X., Zhang, Z., Zhang, F., Ye, Y., Liu, H., Wu, K., et al. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.084 · Cited by 19
CYP 450 enzymes influence (R,S)-ketamine brain delivery and its antidepressant activity
Nguyen, T. M. L., McGowan, J. C., & Gardier, A. M. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108936 · Cited by 17
Ketamine plus Alcohol: What We Know and What We Can Expect about This
Kobayashi, N. H. C., Farias, S. V., Luz, D. A., Ferraro, K. M. M. M., da Conceição, B. C., da Silveira, C. C. S. D. M., Fernandes, L. M. P., Cartágenes, S. D. C., Ferreira, V. M. M., Fontes-Júnior, E. A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147800 · Cited by 19
Guo, H., Tang, L., He, M., Tang, W., Liu, J., Wu, S., Yuan, S., Wang, J., & Tang, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1681060 · Cited by 16
Hancu, G., Uilăcan, A., & Blebea, N. M. (2024) · Drugs and Drug Candidates · doi:10.3390/ddc3040037 · Cited by 16
“It was approved recently by the FDA in 2019 for the treat-ment ® Pharmaceuticals [72,73].”
“Novel Psychopharmacology for Depressive Disorders”
Fornaro, M., Berardis, D. D., Anastasia, A., & Fusco, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-33-6044-0_22 · Cited by 16
New Medications for Neuropsychiatric Disorders
Reddy, H. M., Poole, J. S., Maguire, G. A., & Stahl, S. M. (2020) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2020.02.008 · Cited by 17
Chiappini, S., Guirguis, A., Schifano, N., Corkery, J., Semeraro, F., Mosca, A., D’Andrea, G., Papanti, G. D., Arillotta, D., Floresta, G., et al. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111213 · Cited by 15
“However, major concerns remain regarding an effective protocol to maintain the clinical antidepressant effect of ketamine seen with the acute administration and the safety, including urological, of ketamine and esketamine in the long term (Brucculeri et al., 2023; Molero et al., 2018).”
Chen, H., Zhang, T., Jiang, Y., He, S., & Jin, J. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s502938 · Cited by 16
Novel uses of ketamine in the emergency department
Corwell, B. N., Motov, S. M., Davis, N. L., & Kim, H. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2100883 · Cited by 16
He, Z., Yu, H., Wu, H., Su, L., Shi, K., Zhao, Y., Zong, Y., Chen, W., & Du, R. (2022) · Pharmaceutical Biology · doi:10.1080/13880209.2022.2099429 · Cited by 15
“These drugs have the disadvantages of a single target (David and Gourion 2016; Molero et al. 2018; Rothmore 2020).”
BackgroundAgomelatine, Ketamine and Vortioxetine Attenuate Energy Cell Metabolism—In Vitro Study
Ľupták, M., Fišar, Z., & Hroudová, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213824 · Cited by 15
“Moreover, it was shown that KET can increase BDNF expression and synthesis [14].”
BackgroundLapa, C. D. O., Viola, T. W., Delfino, R. S., Dutra, L., Rubira, G., Rodrigues, R. J. K., Castro, S. C. C., Ramos‐Quiroga, J. A., & Spanemberg, L. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121257 · Cited by 15
Self-citationDrugs with glutamate-based mechanisms of action in psychiatry
Chrobak, A. A., & Siwek, M. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00656-8 · Cited by 14
Moore, T. M., Walker, K. C., Tung, E., Teed, A. R., Hell, F., Kinreich, S., Jung, R., Abdel, F., Hanson, R. W., & Ahmed, S. S. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.04.041 · Cited by 15
Vendrell-Serres, J., Soto-Angona, Ó., Rodríguez‐Urrutia, A., Arteaga-Henríquez, G., & Ramos‐Quiroga, J. A. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211022187 · Cited by 14
Self-citationGarcía‐Gutiérrez, M. S., Navarro, D., Torregrosa, A. B., Viudez‐Martínez, A., Giner, S., & Manzanares, J. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.07.003 · Cited by 16
Jianjing, Z., Tian, H., Li, J., Sheng-zhang, J., Chen, S., Zhu, J., Jiang, D., Wang, L., Li, G., Chen, M., et al. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.112907 · Cited by 15
“Tolerance is usually related to the hyperactivity of the amygdala, which is an important index of addiction risk (Jasinska et al.,2014; Molero et al., 2018).”
InfluentialPsychiatry might need some psychedelic therapy
Johnson, M. W. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1509544 · Cited by 17
Zhang, Z.-N., Hao, X.-Y., Cai, C., Sun, L., Zhang, Z., Wang, M., Wu, Y., Wang, Y., Cao, J., Liu, Y., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108047 · Cited by 16
Comai, S., Martin, S. D., Mattarei, A., Guidetti, C., Pappagallo, M., Folli, F. B., Alimonti, A., & Manfredi, P. L. (2024) · Pharmaceuticals · doi:10.3390/ph17121618 · Cited by 14
“The adverse effects of intranasal esketamine, such as short-lived dissociative effects in over 70% of patients, require inpatient clinical observation following administration [34].”
InfluentialWu, Y., Yang, Y., Wang, X., Li, S., Hei, Y., Zou, Y., Ye, Z., & Yu, Z. (2025) · BMC Anesthesiology · doi:10.1186/s12871-025-03180-1 · Cited by 14
Jewett, B. E., & Thapa, B. (2018) · StatPearls · Cited by 21
Esketamine–A quick-acting novel antidepressant without the disadvantages of ketamine
Shoib, S., Kotra, M., Javed, S., Nguyen, V.-S., & Malathesh, B. C. (2022) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2021-0099 · Cited by 13
Gutiérrez-Rojas, L., Vendrell-Serres, J., Ramos‐Quiroga, J. A., Etxeandia-Pradera, J.-I., Aguilar, E. J., de Santiago-Díaz, A. I., Hernández-Huerta, D., Tordera, V., Ventoso, C. V., Bolívar, M., et al. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241267837 · Cited by 13
“In this regard, it is necessary to use other evidence-based antidepressant treatments, such as esketamine intra-nasal (ESK-IN) (Molero et al., 2018), a non-selective and non-competitive antagonist of the N -methyl- d -aspartate receptors of GABA (Gamma-aminobutyric acid) inhibitory interneurons.”
Self-citationThe possible place for psychedelics in pharmacotherapy of mental disorders
Wojtas, A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00550-9 · Cited by 14
Effect of esketamine on reducing postpartum pain and depression
Lucke-Wold, B., & Karamian, A. (2025) · World Journal of Clinical Cases · doi:10.12998/wjcc.v13.i7.100422 · Cited by 8
Qiu, L., Chen, X., Fu, J., Chen, X., & Wang, X. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-06035-0 · Cited by 13
“Activation of the mTOR pathway leads to increased protein synthesis and synaptogenesis, which are essential for the rapid onset of antidepressant action [25].”
Geng, X., Pu, Y., Hu, Z., Zhang, H., Wang, M., Fang, C., Lv, G., Li, W., Zhang, X., Fan, X., et al. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s510222 · Cited by 12
“39 A randomized trial showed that intraoperative infusion of esketamine improved the incidence of POSD in patients undergoing gynecologic laparoscopic surgery.”
Vendrell-Serres, J., Soto-Angona, Ó., Rodríguez‐Urrutia, A., Inzoli, B., González, A., & Ramos‐Quiroga, J. A. (2023) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.23.1097 · Cited by 12
“This mechanism of action is thought to increase synaptogenesis and modulate inflammation through mediators such as the increase in the secretion of blood-derived neurotrophic factor (BDNF) [11].”
BackgroundSelf-citationPiperlongumine produces antidepressant-like effects in rats exposed to chronic unpredictable stress
Zhang, L., Liu, C., Yuan, M., Huang, C., Chen, L., Su, T., Liao, Z., & Gan, L. (2019) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000498 · Cited by 12
“Esketamine was recently reported to exert rapid antidepressant effect and was the first glutamatergic drug approved by the US Food and Drug Administration for treating patients with treatment-resistant depression (Daly et al., 2018; Molero et al., 2018).”
BackgroundProtocolo diagnóstico y terapéutico de la depresión
Pereira-Sánchez, V., & Santos, P. M. (2019) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2019.09.015 · Cited by 11
Niu, X., Zheng, Y., Wang, W., Zhang, L., Wang, S., Lu, X., Wang, J., Yang, G., Zhao, T. C., Li, Q., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70145 · Cited by 10
“Other currently confirmed or potential targets of ESK includeGRIN2B [25], EEF2 [25], BDNF [25, 26], and the BDNF/NT-3 receptor (NTRK2, TrkB) [25, 26].”
Safety considerations and risk mitigation strategies for ketamine use: a comprehensive review
Sayad, R., Elsaeidy, A. S., Anis, A. M., Atef, M. M., Hawash, E. A., Saad, H. A., Hamad, K., & Kohaf, N. A. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003232 · Cited by 10
Lee, W., Sheehan, C., Chye, R., Chang, S., Bayes, A. J., Loo, C. K. A., Draper, B., Agar, M. R., & Currow, D. C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0290876 · Cited by 11
Yan, S., Li, Q., & He, K. (2024) · BMC Anesthesiology · doi:10.1186/s12871-024-02446-4 · Cited by 10
“Esketamine, a racemic isomer of ketamine, exhibits fewer adverse effects and shorter sedation periods compared with racemic ketamine [22], for instance produces less psychiatric adverse reactions [23], while demonstrating approximately twice the efficacy of its counterpart [24].”
BackgroundAl‐Alawi, M., Brietzke, E. M., Carvalhal, A., & Soares, C. N. (2020) · Reviews in the Neurosciences · doi:10.1515/revneuro-2020-0001 · Cited by 11
Li, H., Xu, W.-J., Wang, Y., Xie, S., & Wang, H. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1476449 · Cited by 10
Ketamine as a Treatment Option for Severe Borderline Personality Disorder: A Case Report
Rogg, H. V., Avram, M., Müller, F., Junghanns, K., Borgwardt, S., & Zurowski, B. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001642 · Cited by 9
Efficacy of ketamine versus esketamine in the treatment of perioperative depression: A review
Wen, W., Zhao, W., Xia, X., Duan, X., Zhang, L., Lin, D., Qi, Z., Wang, S., Gao, M., Liu, C., et al. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173773 · Cited by 9
Liu, J., Hu, A., Yang, Y., Huang, S., Mao, J., Liu, Y., Chen, C., Cheng, Z., & Liu, W. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104518 · Cited by 10
Fey, S. J., Korzeniowska, B., & Wrzesinski, K. (2020) · Toxicology Research · doi:10.1093/toxres/tfaa033 · Cited by 10
Li, Y., Zhao, K., Cao, P., Wang, Q., Li, K., Zhang, J., & Zhou, J. (2025) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-025-07809-4 · Cited by 10
“Esketamine has a greater affinity for NMDARs than ketamine and provides analgesic effects approximately 1 · 5–2 times stronger [42, 43].”
Current drug targets for the treatment of depression
Pathak, G., Nigade, A., Anitha, K., & Bhatt, S. (2025) · Brain Disorders · doi:10.1016/j.dscb.2025.100270 · Cited by 9
Yuan, B., Tian, S., Pu, X., Yin, J., Wang, M., Feng, S., Lv, X., Sun, Y., Yao, H., Li, M., et al. (2025) · Sleep Medicine · doi:10.1016/j.sleep.2025.106852 · Cited by 8
Progress in the Application of Esketamine During the Perioperative Period
Wang, J., Hu, Q., Cao, R.-Y., Liu, W.-K., Guo, M., Lin, Y., Zhong, M., Liang, W., & Wang, L. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s579462 · Cited by 8
“101 Hysteroscopy Hysteroscopy is a widely used modality for the diagnosis and treatment of gynecological diseases, and esketamine provides effective sedation and analgesia for this type of procedure.”
Wei, Q., Chen, C., Zhu, J., Mei, B., & Liu, X. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-075767 · Cited by 8
“16 19 The Food and Drug Administration has approved esketamine for the management of treatment-resistant and suicidal depression.”
BackgroundLi, K., Chai, Z., Deng, C., Niu, G., Geng, X., Zhang, Y., Wang, Y., & Wang, T. (2025) · BMC Anesthesiology · doi:10.1186/s12871-024-02846-6 · Cited by 8
“Esketamine is a rotary isomer of ketamine that has an affinity for NMDA receptors whose analgesic effect is approximately 1.5 to 2 times that of ketamine [7–9].”
InfluentialNovel ketamine analogues cause a false positive phencyclidine immunoassay
Skaugen, J. M., Scoccimarro, A. D., Pizon, A. F., Rymer, J. A., Giannoutsos, S., Ekins, S., Krasowski, M. D., & Tamama, K. (2019) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563219858125 · Cited by 8
Esketamine Nasal Spray for Treatment-Resistant Depression
Fantasia, H. C. (2020) · Nursing for Women s Health · doi:10.1016/j.nwh.2020.03.004 · Cited by 8
Du, J., Liu, N., Ma, L., Liu, R., Zuo, D., Lan, X., Yang, J., Wei, W., Peng, X., & Yu, J. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116176 · Cited by 8
Zhuo, C., Lin, X., Tian, H., Liu, S., Bian, H., & Chen, C. (2020) · Brain and Behavior · doi:10.1002/brb3.1600 · Cited by 8
“Previous studies have also reported that a single ketamine treatment may alleviate treatment-resistant depression by normalizing aberrant activity in DMN components and in the frontal cortex (Maltbie et al., 2017; Mueller et al., 2018; Murrough et al., 2015).”
BackgroundKetamine in the Treatment of Major Depressive Disorder
Luu, B., Rice, E. I., & Goldin, P. R. (2019) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2019.07.016 · Cited by 7
Early optimized pharmacological treatment in patients with depression and chronic pain
Oluboka, O. J., Katzman, M. A., Habert, J., Khullar, A., Oakander, M. A., McIntosh, D., McIntyre, R. S., Soares, C. N., Lam, R. W. M., Klassen, L. J., et al. (2022) · CNS Spectrums · doi:10.1017/s1092852922000128 · Cited by 10
Souza, A. J., Cortez, I. L., da Silva, N. R., Pedrazzi, J. F. C., Domingos, L. B., Braga, M. S., Santos‐Silva, T., Bel, E. A. D., Resstel, L. B. M., Li, G., et al. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.113832 · Cited by 7
Jiang, J., Wang, Z., Dong, Y., Yang, Y., Ng, C. H., Ma, S., Xu, Y., Hu, H., & Hu, S. (2019) · Medicine · doi:10.1097/md.0000000000016674 · Cited by 7
“However, ketamine is classified as a psychoactive drug due to its potential addiction,([6]) which may limit its application in clinical practice.”
BackgroundGómez‐Revuelta, M., Fernández-Rodríguez, M., Antón, L. B., & Vázquez-Bourgón, J. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320981498 · Cited by 7
McKarns, S. C. (2022) · Current Clinical Pharmacology · doi:10.2174/2772432817666220301104118 · Cited by 7
Prevention of Suicidal Behavior in Bipolar Disorder
Tondo, L., Vázquez, G. H., & Baldessarini, R. J. (2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.23021025 · Cited by 7
Liu, X., & Read, S. J. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1349576 · Cited by 9
“Esketamine and other pharmacotherapies are nascent treatments with promise for ef fi cacy, but some researchers still question long-term safety and tolerability (117).”
BackgroundDepression, an unmet health need in Africa: Understanding the promise of ketamine
Millen, A. M. E., Daniels, W. M. U., & Baijnath, S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28610 · Cited by 8
“In recent years, ketamine has been shown to remarkably improve clinical depressive symptoms in patients with TRD [49].”
BackgroundIrwin, M. N., & VandenBerg, A. (2021) · Mental Health Clinician · doi:10.9740/mhc.2021.05.200 · Cited by 7
“Alternatively, ketamine, an Nmethyl-D-aspartate receptor (NMDAR) antagonist originally developed for anesthetic use, exhibits antidepressant action within hours of administration in some patients.(11,12) The rapid onset of antidepressant effects associated with ketamine has led to off-label use of racemic ketamine as…”
BackgroundThe role of anesthesiologists in postpartum depression: current perspectives and future directions
Du, W., Qian, X., Xu, Z., & Liu, Z. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1511817 · Cited by 8
Wang, Y. (2024) · American Journal of Translational Research · doi:10.62347/rrzf5229 · Cited by 6
Huang, X.-M., & Qiu, H.-X. (2024) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2024.2413855 · Cited by 6
“However, recent preclinical and clinical data suggest that many of ketamine’s adverse effects are primarily associated with Esketamine rather than R-ketamine [20,21].”
Mundorf, A., Matsui, H., Ocklenburg, S., & Freund, N. (2022) · Symmetry · doi:10.3390/sym14112352 · Cited by 7
Esketamine clinical trials: reply to Maju et al.
Gastaldon, C., Papola, D., Ostuzzi, G., & Barbui, C. (2020) · Epidemiology and Psychiatric Sciences · doi:10.1017/s204579602000027x · Cited by 6
Subanesthetic ketamine with an AMPAkine attenuates motor impulsivity in rats
Davis-Reyes, B. D., Smith, A. E., Xu, J., Cunningham, K. A., Zhou, J., & Anastasio, N. C. (2021) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000623 · Cited by 7
“These data suggest that ketamine plus HJC0122 can substantially normalize motor impulsivity at lower therapeutic doses, which is an important consideration, as repeated/higher dosing regimens are often accompanied by increased risk for negative side effects (Molero et al., 2018).”
BackgroundWang, X., Li, L., Zhang, X., & Gao, J. (2021) · Human & Experimental Toxicology · doi:10.1177/09603271211051602 · Cited by 6
Collo, G., Cavalleri, L., & Pich, E. M. (2019) · Chronic Stress · doi:10.1177/2470547019842545 · Cited by 6
“6,7 Its enantiomer S-ketamine, administrated intranasally, showed rapid antidepressant and antisuicidal effects 8 and was just approved by food and drug administration (FDA).”
BackgroundNew Somatic Treatments for Child and Adolescent Depression
Cullen, K. R., Padilla, L. E., Papke, V. N., & Klimes-Dougan, B. (2019) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-019-00194-8 · Cited by 5
Liu, J., Liu, J., Sun, H., Cheng, X., Wang, C., Lei, D., & Han, C. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1505408 · Cited by 5
Yang, Q., Luo, Q., Cheng, L., Yang, Z.-X., Rao, L.-H., Cheng, F., & Zheng, L.-D. (2025) · Journal of PeriAnesthesia Nursing · doi:10.1016/j.jopan.2025.01.012 · Cited by 5
Wang, X., Xie, T., & Wang, D. (2025) · BMC Anesthesiology · doi:10.1186/s12871-025-03323-4 · Cited by 5
“Esketamine, the dextro-enantiomer of ketamine, exhibits therapeutic potency approximately twice that of ketamine and is characterized by a short recovery period, rapid cognitive recovery, and a low incidence of psychiatric side effects [13, 14].”
Chu, T., Xiaoling, P., Wan, K., Li, M. H., Liu, T., Shi, X., Yao, W., Li, S., Zhou, Z., Yang, C., et al. (2026) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000002348 · Cited by 5
“14,15 Due to its higher potency and fewer side effects, due to the heterogeneity of study cohorts, dosing regimens and the influence of confounding factors.”
Zhang, Y., Song, Z., Zhang, H., Lin, H., Xu, P., Li, Z., He, Q., & Wei, B. (2025) · Biomedicines · doi:10.3390/biomedicines13051081 · Cited by 6
“The intranasal delivery of esketamine demonstrates a pharmacokinetic advantage over oral administration, with absolute bioavailability reaching 48% (versus 8% for oral esketamine) and a significantly reduced time to peak plasma concentration (T max = 0.5–1 h vs. 5–6 h for oral tablets) [139,140].”
InfluentialInfusing Hope Into the Treatment of Suicidality: a Review of Ketamine’s Effects on Suicidality
Rengasamy, M. L., Hsiung, K. S., & Price, R. B. (2019) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-019-00184-3 · Cited by 5
Sałaciak, K., Głuch‐Lutwin, M., Siwek, A., Szafarz, M., Kazek, G., Bednarski, M., Nowiński, L., Mitchell, E. J., Jastrzębska‐Więsek, M., Partyka, A., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120959605 · Cited by 5
“Among antidepressants, escitalopram and esketamine show better pharmacological profile than their R-enantiomers (Molero et al., 2018; Ng et al., 2016).”
BackgroundDo sex and gender matter in the pharmacological treatment of depression?
Seifert, J. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04611-z · Cited by 7
“Unlike all other traditional ADDs that effect serotonergic and noradrengic neuro-transmission, the antidepressant effects of (es)ketamine can manifest within hours of application (Molero et al. 2018).”
Cavalcanti-Ribeiro, P., Souza, L. C. A. M. D., Tavares, V. D. D. O., de Almeida, R. N., Lima, N. B. D. M., Gonçalves, K. T. D. C., Lopes, E. I. T. C., Bolcont, R., de Brito, A. J. C., Falchi-Carvalho, M., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120877 · Cited by 4
Treatment Advances in Perinatal Depression: Innovations and Promising Approaches
Kendall-Tackett, K. A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247744 · Cited by 4
Novel and Emerging Treatments for Agitation in Schizophrenia and Bipolar Disorder
Mashaw, S. A., Anwar, A. I., Vu, J. N., Thomassen, A. S., Beesley, M. L., Shekoohi, S., & Kaye, A. D. (2025) · Healthcare · doi:10.3390/healthcare13080932 · Cited by 4
“Esketamine, an enantiomer of ketamine, could provide a safer alternative to ketamine, as it has a much higher affinity for the NMDA glutamate receptor which allows for a much smaller dose given and decreases the instances of side effects [37].”
Lázaro, R. M., Minguez, T., Reyes-Carrión, A., Gómez, R. J., de la Rosa, D. Á., Bartolomé‐Martín, D., & Giráldez, T. (2025) · The Journal of General Physiology · doi:10.1085/jgp.202513799 · Cited by 4
Shen, M., Ye, X., Chen, K., Lei, W., Huang, Y., Wang, J., Sun, J., & Lu, X. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s540781 · Cited by 4
“10 Furthermore, in vitro studies showed that S-ketamine (such as esketamine) had a four-fold higher affinity for NMDA receptors than R-ketamine, 11 and could reduce the complications typically associated with R-ketamine, such as psycho-tomimetic effects.”
Tao, Q., Shi, Q., Xu, T., & Ye, S. (2025) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986251328673 · Cited by 4
“34,35 Psychiatric adverse effects such as agitation or nightmares were reported when 1.5 mg/kg propofol was combined with 0.2 mg/kg S-ketamine during painless gastrointestinal endoscopy, whereas no such adverse effects happened when propofol was combined with 0.1 mg/kg S-ketamine.”
InfluentialKetamine: Newer Uses Emerge for an Older Drug
Frost, E. A. M. (2019) · Topics in Pain Management · doi:10.1097/01.tpm.0000550594.56362.6d · Cited by 4
Medication for Depression: Monoamine Enhancers and Esketamine (Antidepressants)
Park, S., & Shen, W. W. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_133-1 · Cited by 5
Characteristics of MK-801-induced locomotor sensitization
Li, G., Xu, S., & Kang, U. G. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.05.009 · Cited by 5
Antidepressant Actions of Ketamine and Its Two Enantiomers
Chang, L., Wei, Y., & Hashimoto, K. (2020) · Springer eBooks · doi:10.1007/978-981-15-2902-3_7 · Cited by 4
Dıkeç, G., & Timarcıoğlu, K. (2023) · Trauma Care · doi:10.3390/traumacare3010005 · Cited by 3
“It has been thought that the effects of antidepressants do not start immediately [26], side effects occur first, and individuals think that the medications do not improve them.”
BackgroundMimms, C. S., Sotelo, K., & Khaliq, A. (2025) · Cureus · doi:10.7759/cureus.82532 · Cited by 3
“Meanwhile, psilocybin-assisted psychotherapy is gaining momentum through ongoing clinical trials [5].”
Wang, Z., Li, H., Wang, Y., Li, Y., Li, L., Zhang, L. J., & Luo, T. (2025) · BMC Anesthesiology · doi:10.1186/s12871-025-03236-2 · Cited by 5
“Esketamine, the S-enantiomer of racemic ketamine, exhibits a higher affinity for NMDA receptors compared to ketamine [16].”
Lam, H., Lo, T. L., Yeung, K. L. A., Cheung, N., Cheung, E. F. C., Fu, C. K., Lam, C., Lee, Y. K., Pao, R. S., Sung, W. K., et al. (2025) · Asia-Pacific Psychiatry · doi:10.1111/appy.70010 · Cited by 3
Wang, Y., Liu, C., Wu, Y., Liu, Q., Xu, Z., Jiang, X., Gu, E., Li, Z., Wang, X., & Yao, H. (2026) · BMC Anesthesiology · doi:10.1186/s12871-026-03628-y · Cited by 3
Metadata
- Authors
- Molero, P., Ramos-Quiroga, J. A., Martin-Santos, R., Calvo-Sánchez, E., Gutiérrez-Rojas, L., & Meana, J. J.
- Affiliations
- Navarre Institute of Health Research (ES)
- Universitat Autònoma de Barcelona (ES)
- Universidad de Granada (ES)
- University of the Basque Country (ES)
- Corresponding author
- Molero, P.
- Venue
- CNS Drugs
- Published
- 2018-05
- Volume
- 32
- Issue
- 5
- Pages
- 411-420
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W2800815779
- Cited by
- 280
- References
- 56
- Citations by year
- 2026: 28 · 2025: 45 · 2024: 41 · 2023: 31 · 2022: 31 · 2021: 35 · 2020: 34 · 2019: 26 · 2018: 9
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, esketamine, treatment-resistant depression, NMDA receptor, NR2B subunit, eEF2 kinase, brain-derived neurotrophic factor, mTOR signaling, intranasal administration, antidepressant tolerability, dissociative effects, antisuicidal effects, neurocognitive toxicity, substance use disorder risk, long-term safety
- MeSH terms
- Animals, Antidepressive Agents, Humans, Ketamine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.